clinical trial · NCT00833664
Terbinafine HCl 250 mg Tablet Formulations Under Non-Fasting Conditions
Teva Pharmaceuticals USA·phase1·completed·n = 22
HealthyTerbinafine HCl 250mg tabletsLamisil® 250 mg Tablets
brief summary
The Purpose of this study os to evaluate the relative bioavailability of the test formulation of terbinafine tablets with an already marketed reference formulation Lamisil® (Novartis Pharmaceuticals), under post-prandial conditions in healthy, non-tobacco using male and female adult subjects.
started
Jan 1, 2002
primary completion
Jan 1, 2002
completion
Jan 1, 2002
last updated
May 30, 2023
detailed description
Criteria for Evaluation: FDA Bioequivalence Criteria
Statistical Methods: FDA bioequivalence statistical methods
official title
The Relative Bioavailability of Two Terbinafine HCl 250 mg Tablet Formulations Under Non-Fasting Conditions
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol